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LETTERS TO THE EDITOR 
Inhaled nitric oxide after Glenn and Fontan 
procedures 
To the Editor: 
I read with interest the article by Gamillscheg and 
associates 1 concerning the use of inhaled nitric oxide in 
patients with high systemic venous pressures after a 
bidirectional Glenn shunt or modified Fontan proce- 
dure. When inhaled, nitric oxide is a selective pulmo- 
nary vasodilator in many patients with increased pul- 
monary vascular resistance. Thus nitric oxide may 
potentially assist patients with right heart failure after 
surgical palliation or repair. The authors correctly state 
that "even a small reactive increase of PVR [pulmonary 
vascular resistance] may cause deleterious systemic 
venous hypertension associated with resistant low car- 
diac output syndrome" in this subset of patients. How- 
ever, their study does not provide any evidence that 
inhaled nitric oxide improved the immediate or long- 
term outcome of their patients. 
Patients were treated with inhaled nitric oxide if the 
pulmonary pressure exceeded 20 mm Hg or the 
transpulmonary pressure gradient exceeded 10 mm Hg. 
There were no controls to determine whether these 
elevated pressures may have spontaneously improved 
without inhaled nitric oxide therapy. Further, the au- 
thors did not determine whether patients had signifi- 
cant pulmonary endothelial dysfunction at the onset of 
therapy. After 12 to 18 hours, therapy was abruptly 
withdrawn for 5 minutes and hemodynamic and oxygen- 
ation measurements were repeated. The authors used 
these data to calculate significant "improvements" in
pulmonary pressure, transpulmonary pressure gradient, 
and oxygenation. Unfortunately, the acute changes 
after nitric oxide withdrawal may have simply resulted 
from the suppression of endogenous nitric oxide pro- 
duction by inhalation therapy) 
Goldman and associates 3 have also reported a favor- 
able hemodynamic effect of inhaled nitric oxide in 
patients after the fenestrated Fontan procedure. Un- 
fortunately, they also had no controls and 50% of their 
patients with an oxygen saturation less than 85% sub- 
sequently died. Nonetheless, they recommend that ni- 
tric oxide be used after a fenestrated Fontan procedure 
if the oxygen saturation is less than 85% and/or the 
transpulmonary gradient exceeds 12 mm Hg. Perhaps 
appropriate patient selection may be a more effective 
alternative than inhaled nitric oxide in the palliation of 
functional single ventricle. 
In my opinion, the beneficial effects of inhaled nitric 
oxide in patients with postoperative pulmonary hy- 
pertension have been overstated and not adequately 
documented by even small controlled studies. The 
reports of Gamillscheg, 1 Goldman, 3 and their associ- 
ates underscore the need for carefully designed studies 
in determining the safety and efficacy of inhaled nitric 
oxide. 
Ronald Day, MD 
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University of Utah 
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Salt Lake City, UT 84113 
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Reply to the Editor: 
We would like to thank Dr. Day for his comments 
relating to our article. 1On the basis of our study design, 
we cannot rule out whether the elevated central venous 
pressures and the transpulmonary pressure gradients may 
not have spontaneously improved without inhaled nitric 
oxide treatment in our study patients. However, diag- 
noses, preoperative s lection criteria (in particular pulmo- 
nary vascular esistance), surgical technique, and periop- 
erative and postoperative management of the study 
patients did not differ from those of other patients under- 
going the Fontan procedure during the study period; these 
patients did not meet our selection criteria for nitric oxide 
treatment: central venous pressure greater than 20 mm 
Hg or transpulmonary pressure gradient greater than 10 
mm Hg. As stated in our article, treatment with inhaled 
nitric oxide was started after conventional therapy had 
failed to improve the hemodynamic state. Previously, 
Kirklin and associates 2 demonstrated a continuous rela- 
tion between elevated right atrial pressures early after the 
Fontan operation and the probability of death or take- 
down within 30 days after the operation. They reported a
probability of death or Fontan takedown of 38% and 52% 
when the right atrial pressure 3 hours after operation 
exceeded 20 and 22 mm Hg, respectively. Only one of our 
13 patients died in the early postoperative period. This 
patient died of cerebral hemorrhage 5 days after being 
weaned from nitric oxide therapy, in stable hemodynamic 
condition. Among the remaining 12 patients, there was 
only one late death, which occurred 14 months after the 
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